From: Assessing the validity of tuberculosis surveillance data in California
#* | Report of Verified Case of Tuberculosis (RVCT) Variable | RVCT Missing/Unknown % (95% CI)† | Public Health Medical Record Missing/Unknown % (95% CI) | ||
---|---|---|---|---|---|
DEMOGRAPHIC | |||||
1 | Sex | 0.0 | -‡ | 0.0 | - |
2 | Race | 0.0 | - | 1.3 | (0.7, 2.6) |
3 | Ethnicity | 0.0 | - | 1.4 | (0.7, 2.6) |
Country of origin | |||||
4 | U.S.-born | 0.6 | (0.2, 1.5) | 2.7 | (1.7, 4.2) |
5 | Other country of origin | 0.0 | - | 0.1 | (0.1, 0.1) |
6 | Occupation | 8.2 | (6.3, 10.6) | 23.6 | (20.4, 27.1) |
7 | Resident of long-term care facility at diagnosis | 0.2 | (0.1, 0.4) | 7.6 | (5.8, 9.9) |
8 | Resident of correctional facility at diagnosis | 0.1 | (0.0, 0.3) | 6.7 | (5.1, 8.9) |
SOCIAL/BEHAVIORAL RISK FACTORS | |||||
9 | Homeless within past 1–2 years§ | 1.9 | (1.1, 3.2) | 63.8 | (59.9, 67.5) |
10 | Injecting drug user within past year | 8.0 | (6.2, 10.2) | 22.1 | (19.1, 25.4) |
11 | Non-injecting drug user within past year | 7.8 | (6.0, 10.0) | 23.4 | (20.3, 26.8) |
12 | Excess alcohol use within past year | 7.6 | (5.9, 9.8) | 24.1 | (21.0, 27.6) |
DIAGNOSTIC AND CLINICAL | |||||
13 | Previous TB | 0.0 | - | 19.7 | (16.8, 22.9) |
14 | Site of disease | 0.0 | - | 0.0 | - |
15 | Sputum smear|| | 4.9 | (3.4, 7.2) | 6.0 | (4.2, 8.7) |
16 | Sputum culture|| | 15.1 | (12.1, 18.7) | 14.4 | (11.5, 17.8) |
17 | Smear of tissue/body fluids (non-sputum)|| | 0.6 | (0.3, 1.5) | 78.9 | (75.6, 82.0) |
18 | Tissue/body fluid type (non-sputum)* * | 0.0 | - | 0.0 | - |
19 | Culture of tissue/other body fluid (non-sputum)|| | 0.3 | (0.1, 1.1) | 63.6 | (59.8, 67.2) |
20 | Tissue/body fluid type (non-sputum) * * | 0.0 | - | 0.0 | - |
Chest x-ray results | |||||
21 | Abnormal/normal|| | 0.6 | (0.3, 1.5) | 8.7 | (6.8, 11.2) |
22 | If abnormal: cavitary/non-cavitary** | 0.1 | (0.0, 0.4) | 0.0 | - |
23 | If abnormal: stable/worsening/improving** | 68.9 | (64.8, 72.7) | 45.3 | (40.9, 49.7) |
24 | Initial susceptibility testing done | 0.0 | - | 1.7 | (0.9, 3.1) |
Results of initial susceptibility testing, if done†† | |||||
25 | Isoniazid|| | 0.0 | - | 3.1 | (2.0, 4.9) |
26 | Rifampin|| | 0.7 | (0.3, 1.8) | 21.2 | (18.1, 24.5) |
27 | Pyrazinamide|| | 0.0 | - | 3.1 | (2.0, 4.9) |
28 | Ethambutol|| | 0.0 | - | 4.1 | (2.8, 6.0) |
29 | Streptomycin|| | 0.0 | - | 2.9 | (1.8, 4.6) |
TREATMENT AND CASE MANAGEMENT | |||||
Initial treatment regimen | |||||
30 | Isoniazid | 0.0 | - | 0.0 | - |
31 | Rifampin | 0.0 | - | 0.0 | - |
32 | Pyrazinamide | 0.1 | (0.0, 0.3) | 0.0 | - |
33 | Ethambutol | 0.0 | - | 0.0 | - |
34 | Streptomycin | 0.1 | (0.0, 0.3) | 0.0 | - |
35 | Sputum culture conversion, if ever sputum culture positive** | 1.6 | (0.7, 3.5) | 0.0 | - |
36 | Reason therapy stopped | 0.7 | (0.3, 1.5) | 0.0 | - |
37 | Provider type | 0.2 | (0.0, 1.3) | 0.0 | - |
38 | Therapy administration | 3.5 | (2.4, 5.2) | 0.0 | - |
39 | Final susceptibility testing done‡‡ | 0.0 | - | ||
Results of final susceptibility testing, if done‡‡ | |||||
40 | Isoniazid||‡‡ | 0.0 | - | 5.7 | (1.5, 19.6) |
41 | Rifampin||‡‡ | 0.0 | - | 5.7 | (1.5, 19.6) |
42 | Pyrazinamide||‡‡ | 5.1 | (0.9, 25.2) | 11.9 | (4.9, 26.2) |
43 | Ethambutol||†† | 0.0 | - | 6.4 | (1.9, 19.3) |
44 | Streptomycin||‡‡ | 0.0 | - | 9.8 | (3.3, 25.4) |
DATES | |||||
45 | TB case report date | 0.0 | - | 5.7 | (4.1, 7.8) |
46 | Date of birth | 0.0 | - | 0.1 | (0.0, 0.3) |
47 | Date arrived in United States (foreign-born cases)** | 9.2 | (7.0, 12.1) | 15.1 | (12.1, 18.6) |
48 | Treatment start date | 0.0 | - | 0.0 | - |
49 | Date specimen collected for initial drug susceptibility testing** | 0.0 | - | 2.1 | (1.2, 3.7) |
50 | Date specimen collected on initially positive sputum culture** | 0.0 | - | 0.0 | - |
51 | Date specimen collected on first consistently negative sputum culture** | 1.4 | (0.5, 3.8) | 0.2 | (0.2, 0.2) |
52 | Date TB treatment stopped | 0.2 | (0.2, 0.2) | 0.0 | - |
53 | Date specimen collected for final drug susceptibility testing††‡‡ | 5.1 | (0.9, 25.2) | 9.8 | (3.3, 25.4) |